A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS) Meeting Abstract
| Authors: | Luger, S. M.; O'Connell, C. L.; Klimek, V.; Cooper, M. A.; Besa, E. C.; Rossetti, J. M.; Reid, G. K.; Humphrey, R.; Martell, R. E.; Garcia-Manero, G. |
| Abstract Title: | A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS) |
| Meeting Title: | 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 31 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2013 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2013-05-20 |
| Language: | English |
| ACCESSION: | WOS:000335419602473 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2013.31.15_suppl.7116 |
| Notes: | Meeting Abstract: 7116 -- Source: Wos |
